235 related articles for article (PubMed ID: 8261116)
1. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.
Benazzouz A; Gross C; Féger J; Boraud T; Bioulac B
Eur J Neurosci; 1993 Apr; 5(4):382-9. PubMed ID: 8261116
[TBL] [Abstract][Full Text] [Related]
2. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C
Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087
[TBL] [Abstract][Full Text] [Related]
3. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Bergman H; Wichmann T; DeLong MR
Science; 1990 Sep; 249(4975):1436-8. PubMed ID: 2402638
[TBL] [Abstract][Full Text] [Related]
4. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
Wichmann T; Bergman H; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):521-30. PubMed ID: 7983516
[TBL] [Abstract][Full Text] [Related]
5. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR
Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750
[TBL] [Abstract][Full Text] [Related]
6. Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
Mathai A; Ma Y; Paré JF; Villalba RM; Wichmann T; Smith Y
Brain; 2015 Apr; 138(Pt 4):946-62. PubMed ID: 25681412
[TBL] [Abstract][Full Text] [Related]
7. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
8. MPTP induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies.
Benazzouz A; Gross C; Dupont J; Bioulac B
Exp Brain Res; 1992; 90(1):116-20. PubMed ID: 1355743
[TBL] [Abstract][Full Text] [Related]
9. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.
Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
Brain Res; 1985 May; 335(1):194-9. PubMed ID: 3873977
[TBL] [Abstract][Full Text] [Related]
10. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
11. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
Bergman H; Wichmann T; Karmon B; DeLong MR
J Neurophysiol; 1994 Aug; 72(2):507-20. PubMed ID: 7983515
[TBL] [Abstract][Full Text] [Related]
12. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
[TBL] [Abstract][Full Text] [Related]
13. [Spontaneous saccades in MPTP-induced hemi-parkinsonian monkeys].
Usui S; Fukuda H; Hikosaka O
Rinsho Shinkeigaku; 1990 Nov; 30(11):1181-9. PubMed ID: 2085922
[TBL] [Abstract][Full Text] [Related]
14. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Goldberg JA; Boraud T; Maraton S; Haber SN; Vaadia E; Bergman H
J Neurosci; 2002 Jun; 22(11):4639-53. PubMed ID: 12040070
[TBL] [Abstract][Full Text] [Related]
15. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
16. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180
[TBL] [Abstract][Full Text] [Related]
17. Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion.
Schneider JS; Lidsky TI; Hawks T; Mazziotta JC; Hoffman JM
Brain Res; 1995 Feb; 672(1-2):112-7. PubMed ID: 7749732
[TBL] [Abstract][Full Text] [Related]
18. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
Life Sci; 1987 Apr; 40(17):1657-64. PubMed ID: 3494179
[TBL] [Abstract][Full Text] [Related]
19. Subthalamotomy improves MPTP-induced parkinsonism in monkeys.
Guridi J; Herrero MT; Luquin R; Guillen J; Obeso JA
Stereotact Funct Neurosurg; 1994; 62(1-4):98-102. PubMed ID: 7631095
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
Bezard E; Boraud T; Bioulac B; Gross CE
Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
